Analysis of the drugs available for the pharmacological treatment of patients with covid-19
DOI:
https://doi.org/10.37497/ijhmreview.v7i2.259Keywords:
Pharmacology, Covid-19, Coronavirus, Pandemics.Abstract
Background: Both the new coronavirus (SARS-CoV-2), the etiological agent, and the pandemic disease caused by it, COVID-19, are currently the most studied subjects in the world, due to the fact that they caused and continue to cause millions of deaths worldwide. To date, many drugs have been and are being used to treat patients with COVID-19, some with proven scientific efficacy, others with questioned efficacy, in order to reduce the signs and symptoms caused by COVID-19, the spread of the disease and the number of deaths caused by this disease. Aim: To carry out a literature review on the main drugs available for the pharmacological treatment of patients affected by COVID-19. Method: To carry out this work, scientific articles available in the main scientific databases, such as PubMed, Scielo, Science Direct and Google Scholar, were used. Results and Discussion: So far, many classes of drugs are being tested, among which we can highlight antiviral, anti-inflammatory, antibiotic, anticoagulant, antimalarial, antiparasitic drugs. However, it is worth noting that none of these classes has been shown to be effective in isolation or in association with the prophylaxis of COVID-19, in vivo, according to studies published so far. In addition, we highlight that some drugs are being questioned in several studies because they do not cause a significant improvement in patients undergoing pharmacotherapy. Some drugs covered in this article are undergoing clinical studies, while others, for the time being, have only been studied in in vitro tests. Conclusion: Several classes of drugs have been used in the treatment of patients with COVID-19, but so far, none of the pharmacological tested classes has been shown to be statistically effective in the prophylaxis of COVID-19, as has not yet been found. a drug with effective antiviral action capable of combating SARS-CoV-2.
Downloads
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms: The author(s) authorize the publication of the text in the journal; The author(s) guarantee that the contribution is original and unpublished and is not in the process of being evaluated by any other journal(s); The journal is not responsible for the opinions, ideas, and concepts contained in the texts, as these are the sole responsibility of their respective author(s); The editors reserve the right to make adjustments to the text in order to ensure that it adheres to the standards of the journal. Authors retain the copyrights and grant the journal the right of first publication, with the article simultaneously licensed under the Creative Commons Attribution License which allows the sharing of the article with the acknowledgment of authorship and initial publication in this journal. Authors are authorized to take additional contracts separately, for the non-exclusive distribution of the version of the article published in this journal (e.g. publication in an institutional repository or as a book chapter), with the acknowledgment of authorship and initial publication in this journal.
Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal webpage) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and citation of published work (See The Effect of Free Access at http://opcit.eprints.org/oacitation-biblio.html)
